Testosterone for Menopause: ALEG Position Statement on Evidence

Bioidentical Hormones for Menopause: A New Position Statement Separates Evidence from Hype

The term “bioidentical hormones” often appears in menopause discussions, promising personalized, “natural” relief. A new position statement from the Latin American Association of Gynecological Endocrinology (ALEG) analyzes the evidence for one specific bioidentical hormone—Testosterone—in midlife women. Their findings draw a clear line between clinical use and unproven, potentially risky practices.

Position Statement Condemns Unregulated Compounded Testosterone

Led by Dr. Silvina Pilnik of the Hospital Italiano de Buenos Aires, the ALEG committee identified a significant regulatory gap. No androgen products are specifically approved for women in Latin America. This vacuum has led to the use of products formulated for men or compounded, non-standardized “bioidentical” preparations. The statement, published in Climacteric, explicitly advises against subcutaneous pellets and compounded “bioidentical” Testosterone, citing risks of supraphysiological dosing and insufficient evidence for safety and efficacy. This warning targets a popular but poorly regulated segment of the hormone therapy market.

Compounding pharmacies create custom hormone blends marketed as natural and tailored. However, without the rigorous quality control and standardized dosing of regulated pharmaceuticals, these preparations can deliver erratic hormone levels. Supraphysiological—or above normal—Testosterone levels can trigger side effects like acne, hair growth in unwanted areas, and adverse impacts on cholesterol. The committee’s strong stance is based on a review of international guidelines and meta-analyses from 2000 to the present.

Clear, Narrow Indication for Testosterone: Hypoactive Sexual Desire Disorder

The panel’s primary, evidence-backed recommendation is precise. Testosterone therapy for postmenopausal women should be limited to those with a formal diagnosis of hypoactive sexual desire disorder (HSDD). HSDD is not a simple, fleeting drop in libido; it is defined as a persistent deficiency in sexual fantasies and desire causing significant distress. Diagnosis requires a thorough biopsychosocial evaluation to rule out other causes like relationship issues, stress, depression, or other medical conditions. The committee assigned this a Grade A recommendation, meaning it is based on high-quality evidence.

In a move that simplifies clinical practice, the authors strongly advise against routine blood tests to diagnose low Testosterone in women. Levels vary widely and do not reliably correlate with symptoms. A patient’s clinical presentation is more important. However, they do recommend checking a baseline level before starting therapy, a Grade C recommendation based on lower-quality evidence, primarily to exclude the rare case of a woman who already has elevated androgens. This approach is detailed further in our coverage of the specific Latin American position statement on androgen therapy.

Guidance on DHEA Supplements and Treatment Monitoring

The statement clarifies the role of another commonly discussed androgen, dehydroepiandrosterone (DHEA). Sold over-the-counter as a systemic supplement for energy, libido, and anti-aging, the committee found no evidence supporting its use for sexual symptoms in menopausal women (Grade A: High). They endorse only one application: vaginal DHEA, which is a proven, approved treatment for the genitourinary syndrome of menopause (GSM), which includes vaginal dryness and pain. For broader GSM management strategies, readers can explore new GSM treatments beyond lubricants.

For women who do start Testosterone therapy, monitoring is critical. The committee recommends a follow-up within 3-6 weeks to assess symptom response and check Testosterone levels, aiming to keep them within the physiological range for premenopausal women. Transdermal gels or creams are preferred over oral forms, as they avoid first-pass liver metabolism and provide more stable levels. The necessity for this careful monitoring further underscores the risks of unmonitored compounded therapies, where dosing is inconsistent and medical supervision may be lacking.

Practical Implications for Women Seeking Symptom Relief

For women experiencing menopause-related sexual dysfunction, this position statement provides a clear roadmap. The first step is a comprehensive evaluation with a healthcare provider trained in menopausal health to confirm HSDD. If Testosterone therapy is considered, patients must receive counseling that its use is off-label in Latin America, meaning it is being prescribed outside its officially approved regulatory indication.

They should actively avoid practitioners who promote unregulated compounded Testosterone pellets or creams without discussing the evidence and risks. Instead, seeking providers who use regulated transdermal preparations and commit to regular monitoring is the evidence-based path. It is also vital to manage expectations; Testosterone is not a general “wellness” or energy booster for menopause but a specific treatment for a specific condition. The limitations of the evidence are clear: it does not support the use of androgens for cognitive function, mood, fatigue, or general well-being in menopausal women.

This focused approach contrasts with the broader, symptom-targeted strategies seen in other areas of menopausal health, such as using probiotics to ease symptoms via the gut microbiome.

The ALEG statement cuts through marketing claims about bioidentical hormones with a sharp, evidence-based focus. It validates Testosterone as a legitimate therapy for a narrow indication—HSDD—while strongly cautioning against its unregulated, compounded forms. For women, the message is to prioritize medical guidance that relies on standardized treatments and transparent monitoring over unproven, personalized concoctions.

Sources:
https://pubmed.ncbi.nlm.nih.gov/40919649/
https://pubmed.ncbi.nlm.nih.gov/40109076/
https://pubmed.ncbi.nlm.nih.gov/38980733/